Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

WITHDRAWN

Gas Kinetics and Metabolism in Anesthesia During Non Steady State

Lead Sponsor:

University of California, Irvine

Conditions:

Anesthetized Healthy Patients (ASA 1 or 2) in the Supine Position, Excluding Head, Neck and Head Surgeries

Anesthetized Patient With Severe Systemic Disease (ASA 3 or 4)

Eligibility:

All Genders

18+ years

Brief Summary

During clinical anesthesia, it is astonishing that CO2 monitoring consists mainly of end-tidal PCO2 to confirm endotracheal intubation and to estimate ventilation, and O2 monitoring consists of a sing...

Detailed Description

During clinical anesthesia, it is astonishing that CO2 monitoring consists mainly of end-tidal PCO2 to confirm endotracheal intubation and to estimate ventilation, and O2 monitoring consists of a sing...

Eligibility Criteria

Inclusion

  • All adult patients at UCIMC who are undergoing anesthesia and surgery are eligible for the studies
  • Patients must be American Society of Anesthesiologists (ASA) Class 1 or 2 (generally healthy patients). We plan on studying 100 patients, divided into 5 equally numbered groups. A power analysis of the sample size shows the need for minimum of 20 patients. High risk 3 subgroups (ASA 3), approximately 20 adult patients (included within the 100 planned patients), will be investigated for the (1) RQ correlation with arterial blood gas, (2) for the exercise study and (3) for the esophageal Doppler studies. These study groups include patients that are categorized as ASA 1, 2 or 3, (total of 60 patients) however; the total number of ASA 3 patients will not exceed 20. Subjects having surgeries around the head and neck, as well as surgeries that require the patient to lie face down will be excluded from the study
  • Gender and minority status will not be an exclusion factor for any potential study patient

Exclusion

  • Cardiovascular:
  • Significant vascular disease, especially cardiac and cerebral vascular disease
  • Patients will be excluded if they have a history of having a myocardial infarction or cerebral vascular attack
  • Significant hypertension (\> 170 systolic, \> 90 diastolic) (except for the high risk subgroup mentioned before)
  • Pulmonary:
  • Significant asthma (mild persistent or greater according to the National Asthma Education and Prevention Program classification system) chronic obstructive pulmonary disease (COPD) (Stage II: Moderate COPD according to the Global Initiative for Chronic Obstructive Lung Disease classification
  • Worsening airflow limitation, (FEV1 ≤30% ), and usually the progression of symptoms, with shortness of breath typically developing on exertion), bullous lung disease, or raised intra-cranial pressure (except for the high risk subgroup mentioned before)
  • Esophageal Doppler:
  • If localized pathology is present, including pharyngeal tumor or significant esophageal varices, then the esophageal probe will not be used.
  • Emergency cases:
  • Excluded from the study. Only elective patients will be enrolled.
  • Short surgeries:
  • Surgeries that are expected to last 45 minutes or less will be excluded.

Key Trial Info

Start Date :

August 1 2005

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

January 13 2012

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00225381

Start Date

August 1 2005

End Date

January 13 2012

Last Update

March 23 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of California Irvine Medical Center

Orange, California, United States, 92868